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SUMMARY There is evidence that catecholamines may promote the development of cardiac 
hypertrophy in hypertension. To test the hypothesis that adrenaline directly determines left ventricular 
mass, normotensive Wistar rats were made adrenaline-deficient by adrenalectomy and hypertensive 
by administration of glucocorticoid. Blood pressure, 'heart rate, and body weight of the 
adrenalectomised group were not significantly different from a glucocorticoid treated control group 
with intact adrenals. Heart weight was significantly lower in the adrenalectomised rats, but this 
difference disappeared when heart weight was adjusted for body weight. It appears therefore that the 
presence or absence of adrenaline does not significantly affect cardiac mass in the presence of 
hypertension in this animal model. 
Sustained arterial hypertension frequently results in 
the development of myocardial hypertrophy. The 
increased pressure itself, by increasing ventricular 
afterload and wall tension, is thought to be the 
principal stimulus to left ventricular hypertrophy. ' ' 
However, there are circumstances in which cardiac 
hypertrophy develops, progresses, or regresses 
without accompanying appropriate changes in blood 
pressure, suggesting that other factors in addition to 
blood pressure per se may be involved in the 
hypertrophic process.2 There are several lines of 
evidence suggesting that beta adrenoceptor 
stimulation by catecholamines plays a trophic role in 
the genesis of myocardial hypertrophy. 2-10 Current 
work in this laboratory with a model of 
glucocorticoid-induced hypertension in Wistar rats' I 
offered an opportunity to investigate whether cardiac 
mass is smaller in the absence of circulating adrenaline 
\+hen compared with equally hypertensive animals 
able to normally release adrenaline from the adrenals. 
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Methods 
Male normotensive Wistar rats with initial weights of 
approximately 250 g were biadrenalectomised under 
ether anaesthesia and made hypertensive with 
methylprednisolone (Depo-Medrol@ 40 mg ml-', 
Upjohn) 20 mg-kg-' subcutaneously once weekly for 2 
weeks. Deoxycorticosterone pivalate (Percorten-M@ 
25 mgml-', Ciba-Geigy) 10 mgakg-' was also given 
subcutaneously once weekly to prevent 
mineralocorticoid deficiency. Sham operated controls 
prepared by bilateral flank incisions and direct 
visualisation of the adrenal glands received the same 
steroid treatments. All rats had free access to tap water 
and regular rat chow containing 0.113 mmo1.g-' of 
sodium (Indulab@, Buchs, Switzerland). As expected 
from previous experiments,". '* all rats lost weight 
between the initial surgery and the day of experiment 
due to the catabolic effect of the administered 
glucocorticoids. 
The animals were used for experiments 12 to 16 
days after initial surgery. Under light ether anaesthesia 
a PE-50 plastic catheter was implanted in the right iliac 
artery and a PE- 10 catheter in the right iliac vein. Rats 
were then semi-restrained in individual plexiglass 
tubes and allowed to recover from the anaesthesia and 
surgery for 90 min prior to experiments. Mean blood 
134 
Cardiac mass in glucocorticoid-hyperzensive rats 735 
TABLE Characteristics of adrenalectomised and sham-operated rats with glucocorticoid-induced hypertension. 
Mean blood Heart Body Heart Heart weight 
pressure rate weight weight Body weight 
(mmHn) (beats.min-') ( g )  (w) ( w g - ' )  
~ ~~ ~~ 
Adrenalectomised 146f2 456+8 20523 6602 13 3.23f0.07 
n = 29 
Sham-operated 144f2 416+ 1 1  21423 7202 15 3,3650.07 
n = 31 
NS NS NS p = 0.004 NS 
Results expressed as mean k SEM, NS = not statistically significant 
pressure and heart rate were recorded directly through 
the arterial catheter using a pressure transducer (Bell 
and Howell No. 4-327-1, Pasadena, California) 
connected to an electrogalvanometer (Philips 2000, 
Eindhoven, Netherland) and recorded on a Manarp 
150 light-sensitive oscillograph (Electric Institute 
Limited, London). There were 29 animals in the 
adrenalectomised and 31 in the sham-operated group. 
After death the heart was removed, the atria and great 
vessels were excised, the ventricles were opened so all 
surfaces could be blotted free of blood, and the 
ventricles were weighed. 
Results are expressed as mean k standard error of 
the mean (mean k SEM) for each group. For the 
statistical evaluation of differences among groups a 
Student's t test for unpaired data was used. 
Results 
There was no significant difference between 
adrenalectomised and sham-operated groups of rats in 
intra-arterial mean blood pressure, heart rate, or body 
weight on the day of the experiment (table). 
Heart weight of the adrenaline-deficient 
adrenalectomised group of rats was significantly lower 
than that of the sham-operated rats. However, the heart 
weight to body weight ratio was comparable for both 
groups. These results are also shown in the table. 
Discussion 
Several recent studies have examined the role of the 
adrenal glands in the development of cardiac 
hypertrophy in various animal models of 
hypertension. Womble and co-workers have shown 
that elevation of adrenaline in plasma parallels the 
development of cardiac hypertrophy in dogs with 
surgically induced coarctation of the aorta6 and that 
adrenal medullary cholinergic denervation not only 
prevents development of left ventricular hypertrophy 
but results in a decreased heart weighthody weight 
ratio compared to controls. Noradrenaline levels were 
not significantly different in any of the experimental 
groups. The authors implicated adrenaline as the 
specific hormone regulating cardiac It would of 
course, be difficult to understand why a circulating 
factor could exclusively lead to hypertrophy of the left 
heart as it was observed in this model. These authors 
did not report the blood pressures or heart rates of any 
of their experimental or control groups of dogs. In 
other studies it has been shown that the myocardial 
hypertrophy which develops in male Sprague-Dawley 
rats after construction of the abdominal aorta can 
be prevented to a great extent by bilaterally 
adrenalectomising the animals prior to constriction of 
the aorta.8 Removal of only the adrenal medullae 
failed to prevent the hypertrophy, suggesting that the 
adrenalcortical steroids, rather than adrenaline, are 
crucial to the development of cardiac hypertrophy in 
this model.' Blood pressures and heart rates of the 
adrenalectomised and medullectomised rats were 
lower than those of the untreated controls in these 
experiments, and there were also differences in these 
parameters between the rats with aortic coarctation and 
the sham-operated controls. Bilateral adrenal 
demedullation alone or in combination with chemical 
sympathectomy also failed to alter cardiac 
hypertrophy in SHR.9 However, relative myofibril 
volume decreased in the hearts of these rats, 
suggesting that catecholamines are involved in the 
disproportionate growth of myofibrils characteristic of 
cardiac hypertrophy evoked by pressure-overload.' 
Systolic blood pressure in SHR was reduced by 
bilateral adrenal demedullation alone or in 
combination with chemical sympathectomy in 
comparison to sham control SHR in these 
experiments, and blood pressure was substantially 
lower in all Wistar-Kyoto control groups than in the 
SHR groups. Heart rates of the different experimental 
groups were not reported. 
In the experiments reported here, Wistar rats were 
adrenalectomised to render them adrenaline-deficient 
and made hypertensive with exogenous 
glucocorticoid. Small amounts of mineralocorticoid 
were administered to prevent mineralocorticoid 
deficiency. This procedure virtually eliminates 
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circulating adrenaline whereas plasma noradrenaline 
levels are not statistically different compared with 
those of sham-operated control rats.” In contrast to 
the experiments cited above, the adrenalectomised rats 
and their sham-operated controls in this experiment 
had equal blood pressure and heart rates after these 
manipulations, so any observed differences in cardiac 
weight cannot be aaributed to differences in these 
factors. The ratio of heart weight to body weight was 
slightly lower in the adrenaline-deficient rats than in 
the controls, but this difference was not statistically 
significant. This finding suggests that circulating 
adrenaline does not play a major role in regulating 
cardiac mass in rats with glucocorticoid-induced 
hypertension. In view of the results obtained by 
Nichols and his associates,’ the possibility must be 
entertained that the adrenal cortical steroids 
administered to all of our rats sustained the 
development of cardiac mass to a similar extent, 
whether circulating adrenaline was present or absent. 
Alternatively, it is possible that the lack of difference 
in cardiac mass between the two study groups is due to 
a tropic effect of noradrenaline released by terminal 
nerve endings.3. 
In summary, the results of this study suggest that 
presence or absence of adrenaline does not 
significantly affect the development of cardiac mass in 
the presence of glucocorticoid-induced hypertension 
in the Wistar rat. 
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